SCHEMBL21242823

SCHEMBL21242823

CC1(N2COCCOC2)C=C(c2ccccc2)C1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SCD5 Q86SK9 1/20 0.35
ALDH1A1 P00352 3/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 2/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
PRKDC P78527 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21242653 0.66 NPC1 (0.43) NPC1RAB9AALDH1A1LMNAHPGD
Biphenyl SCHEMBL1950579 0.63 ALDH1A1 (0.64) NPC1RAB9AALDH1A1LMNACYP1A2
SCHEMBL14491867 0.62 NPC1 (0.43) NPC1RAB9ASCD5ALDH1A1LMNA
SCHEMBL28096454 0.62 NPC1 (0.47) NPC1RAB9AALDH1A1LMNAHPGD
Biphenyl SCHEMBL22123804 0.61 ALDH1A1 (0.60) NPC1RAB9AALDH1A1LMNACYP1A2
SCHEMBL7032038 0.60 NPC1 (0.41) NPC1RAB9ASCD5ALDH1A1LMNA
SCHEMBL21220408 0.60 LMNA (0.34) ALDH1A1LMNA
SCHEMBL28972364 0.60 HDAC1 (0.39) NPC1RAB9ASCD5ALDH1A1LMNA
Biphenyl SCHEMBL28029327 0.59 ALDH1A1 (0.56) NPC1RAB9AALDH1A1LMNACYP1A2
Biphenyl SCHEMBL28279980 0.59 ALDH1A1 (0.56) NPC1RAB9AALDH1A1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190241524-A1 COMPOUNDS FOR THE TREATMENT OF PAIN JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2019-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241524-A1 COMPOUNDS FOR THE TREATMENT OF PAIN OPRK1, OPRL1, ACHE NPC1 1507/4885RAB9A 3442/4885SCD5 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.